According to Dr Mercola: The U.S. government is already on the hook for about 3.1 million courses of molnupiravir, which it bought for approximately $2.2 billion. The brand name of the oral antiviral is called Lagevrio, which was narrowly approved by the FDA in October 2021. Merck reported in a press release that the drug … Continue reading DOES MERCK’S NEW ORAL COVID DRUG PREVENT HOSPITALIZATION OR MORE PROFIT FOR BIG PHARMA?